Rebound tonometer comparable to Goldmann applanation

Article

IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a recent study.

IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a study published in Investigative Ophthalmology & Visual Science (IOVS).

For this comparison study, researchers from the Medical University of Silesia, in Katowice, Poland, included 192 eyes of 96 patients, 152 of which were healthy and measured IOPs using the Goldmann applanation tonometer (GAT), a rebound tonometer (RT; Icare PRO), and ultra-high-speed Scheimpflug Technology (UHS ST). Corneal pachymetry was also done with a Scheimpflug camera and an ultrasound pachymeter (A-scan Plus, Accutome) as a comparison for Corvis ST pachymetry.

Mean IOPs were 15.6 mmHg (GAT), 15.6 mmHg (RT), and 16.1 mmHg (UHS ST). Mean central corneal thickness (CCT) was 543.7 μm (UHS ST), 547.9 μm (Pentacam) and 556.25 μm (ultrasound pachymeter).

Researchers noted a significant difference between IOP measurements obtained with GAT and RT compared to measurements obtained with the UHS ST (P P = 0.5). In addition, no significant differences were seen in CCT measured via UHS ST, Pentacam and ultrasound pachymeter.

To access the abstract of this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.